Facilities and equipment are not maintained to ensure the purity, quality, strength and identity of the API Specifically, we observed the following deficiencies: .
Inspection Record
Divi's Laboratories — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Failure to conduct a thorough investigation.
Your R&D division guides quality and production to commence activities inconsistent with CGMPs.
Proper controls are not exercised over computerized systems used for analytical testing to ensure drug products meet their specified quality attributes.
Documentation and records are either not maintained or inaccurate/falsified 1.
A record as of the US FDA document published on 2016-12-28. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.